PROK (ProKidney) Marketable Securities: $106.70 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PROK ProKidney Corp PROK
28 GF Score
Price $2.01
! 3 Warning Signs
View Full Analysis

What is ProKidney Marketable Securities?

ProKidney PROK +4.96% 28 Marketable Securities is $106.70 Mil as of Jun. 2026. GuruFocus rates PROK with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. ProKidney's Marketable Securities for the quarter that ended in Jun. 2026 was $106.70 Mil.

ProKidney's annual Marketable Securities declined from Dec. 2023 ($302.30 Mil) to Dec. 2024 ($259.17 Mil) and declined from Dec. 2024 ($259.17 Mil) to Dec. 2025 ($161.48 Mil).

ProKidney  (NAS:PROK) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

ProKidney Marketable Securities Related Terms

ProKidney Marketable Securities Historical Data

* Premium members only.

The historical data trend for ProKidney's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProKidney Marketable Securities Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 302.30 259.17 161.48

ProKidney Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 209.79 176.40 161.48 123.05 106.70
PROK
28GF Score
ProKidney Corp PROK
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProKidney Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $106.70 Mil mean?
ProKidney (PROK) has a Marketable Securities of $106.70 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on ProKidney and its competitors.
Is ProKidney's Marketable Securities too high?
ProKidney's current Marketable Securities is $106.70 Mil. Overall, ProKidney has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ProKidney's Marketable Securities compare to EYPT and ENTA?
ProKidney's Marketable Securities of $106.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on ProKidney and its competitors. ProKidney's current Marketable Securities is $106.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProKidney stock overvalued right now?
ProKidney (PROK) has a current Marketable Securities of $106.70 Mil. The current Marketable Securities is $106.70 Mil. ProKidney's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For ProKidney (PROK), the current Marketable Securities is $106.70 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProKidney Business Description

Other Exchanges PROK:Mexico
Address 2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
28GF Score

Get the complete analysis for PROK

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.01
Price